-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] Recently, Huadong Medicine announced that it has reached a strategic cooperation with Gulf Pharmaceutical Industries PJSC (JULPHAR) (hereinafter referred to as "Julphar"), a Middle Eastern compa.
Julphar will obtain the company's liraglutide injection product for diabetes and weight lo.
Development, production and commercialization interests in 17 countries in the Middle East and North Africa, including the United Arab Emirates, Saudi Arabia, Egypt, Kuwait, Oman, Bahrain,e.
Under the agreement, Huadong Medicine will receive authorization upfront payments, development and registration milestone payments, and an agreed-upon share of net sal.
Julphar, which Huadong Medicine has authorized and cooperated with, is one of the largest pharmaceutical manufacturers in the Middle East and Africa, and one of the world's leading insulin manufacture.
It has always maintained an advantageous position in the production and distribution of pharmaceutical produc.
There are 12 internationally certified manufacturing plants in the emira.
Therefore, the industry expects that Huadong Medicine and Julphar will join hands with each other to make use of each other's advantages to realize the smooth launch of liraglutide injection in the Middle East and North Africa, bringing benefits to more patients around the wor.
It is understood that liraglutide injection is the first-generation GLP-1 receptor agonist produced by Novo Nordisk, and it is also the world's first long-acting GLP-1 receptor agonist, which can be injected once a d.
It was listed in the EU as early as 2009 and was approved by NMPA in China in 201Huadong Medicine's liraglutide is the first domestically-approved liraglutide-like drug, and the second overseas authorized product after TTP27The industry believes that this cooperation marks the international recognition of its diabetes field strength and R&D innovation capabilities aga.
It is an important milestone for the company to integrate into global pharmaceutical R&D innovation, and it is expected to lay a solid foundation for expanding overseas markets in the futu.
In fact, as a leader in diabetes in China, Huadong Medicine has more than 20 hypoglycemic products commercialized and under developme.
In terms of product reserves and target coverage, it has an advantageous position in the industry, and its product pipeline layout has reached the international advanced level, with strong first-mover advantages and comprehensive streng.
Therefore, its research products and commercialization capabilities are also gaining international recognition one after anoth.
In September 2021, Huadong Medicine successfully authorized the global innovative GLP-1 oral small molecule product TTP273 under development to South Korea, with a total amount of up to 39 million US dollars, realizing the company's first license out transacti.
Subsequently, in October 2021, Huadong Medicine also reached a strategic cooperation with Japan's Takeda Pharmaceutical on the commercialization of alogliptin benzoate tablets in China, which further enriched the company's product pipeline in the field of diabetes and formed synergy with the existing key varieties in the field of diabet.
effect, consolidate and enhance the company's market competitiveness in the domestic diabetes specialty drug fie.
According to the Minutes of Investor Activities of Huadong Medicine on April 28, Nisina (Alogliptin Benzoate Tablets) has been in good sales during the marketing process since the beginning of this year, showing a good growth tre.
Xinna is expected to further increase the volume and complete the established sales target for this ye.
In general, the licenseout of this product has proved to the market once again the strong commercialization cooperation ability of Huadong Medici.
The industry expects that Huadong Medicine will continue to demonstrate its advantages in this field in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
Julphar will obtain the company's liraglutide injection product for diabetes and weight lo.
Development, production and commercialization interests in 17 countries in the Middle East and North Africa, including the United Arab Emirates, Saudi Arabia, Egypt, Kuwait, Oman, Bahrain,e.
Under the agreement, Huadong Medicine will receive authorization upfront payments, development and registration milestone payments, and an agreed-upon share of net sal.
Julphar, which Huadong Medicine has authorized and cooperated with, is one of the largest pharmaceutical manufacturers in the Middle East and Africa, and one of the world's leading insulin manufacture.
It has always maintained an advantageous position in the production and distribution of pharmaceutical produc.
There are 12 internationally certified manufacturing plants in the emira.
Therefore, the industry expects that Huadong Medicine and Julphar will join hands with each other to make use of each other's advantages to realize the smooth launch of liraglutide injection in the Middle East and North Africa, bringing benefits to more patients around the wor.
It is understood that liraglutide injection is the first-generation GLP-1 receptor agonist produced by Novo Nordisk, and it is also the world's first long-acting GLP-1 receptor agonist, which can be injected once a d.
It was listed in the EU as early as 2009 and was approved by NMPA in China in 201Huadong Medicine's liraglutide is the first domestically-approved liraglutide-like drug, and the second overseas authorized product after TTP27The industry believes that this cooperation marks the international recognition of its diabetes field strength and R&D innovation capabilities aga.
It is an important milestone for the company to integrate into global pharmaceutical R&D innovation, and it is expected to lay a solid foundation for expanding overseas markets in the futu.
In fact, as a leader in diabetes in China, Huadong Medicine has more than 20 hypoglycemic products commercialized and under developme.
In terms of product reserves and target coverage, it has an advantageous position in the industry, and its product pipeline layout has reached the international advanced level, with strong first-mover advantages and comprehensive streng.
Therefore, its research products and commercialization capabilities are also gaining international recognition one after anoth.
In September 2021, Huadong Medicine successfully authorized the global innovative GLP-1 oral small molecule product TTP273 under development to South Korea, with a total amount of up to 39 million US dollars, realizing the company's first license out transacti.
Subsequently, in October 2021, Huadong Medicine also reached a strategic cooperation with Japan's Takeda Pharmaceutical on the commercialization of alogliptin benzoate tablets in China, which further enriched the company's product pipeline in the field of diabetes and formed synergy with the existing key varieties in the field of diabet.
effect, consolidate and enhance the company's market competitiveness in the domestic diabetes specialty drug fie.
According to the Minutes of Investor Activities of Huadong Medicine on April 28, Nisina (Alogliptin Benzoate Tablets) has been in good sales during the marketing process since the beginning of this year, showing a good growth tre.
Xinna is expected to further increase the volume and complete the established sales target for this ye.
In general, the licenseout of this product has proved to the market once again the strong commercialization cooperation ability of Huadong Medici.
The industry expects that Huadong Medicine will continue to demonstrate its advantages in this field in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
